Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01970865
Registration number
NCT01970865
Ethics application status
Date submitted
16/10/2013
Date registered
28/10/2013
Date last updated
7/06/2023
Titles & IDs
Public title
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Query!
Scientific title
PHASE 1/2 STUDY OF PF-06463922 (AN ALK/ROS1 TYROSINE KINASE INHIBITOR) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS
Query!
Secondary ID [1]
0
0
2013-002620-17
Query!
Secondary ID [2]
0
0
B7461001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Treatment: Drugs - PF-06463922
Treatment: Drugs - Crizotinib
Experimental: PF-06463922 -
Other: Crizotinib - ALK+ NSCLC patients who are treatment naïve may be eligible to receive crizotinib following PF-06463922 as a substudy to the main study.
Treatment: Drugs: PF-06463922
Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days
Treatment: Drugs: Crizotinib
Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1
Query!
Assessment method [1]
0
0
DLT was defined as any of the following adverse events (AEs) attributable to PF-06463922: (1) hematologic: grade 4 neutropenia for >7 days; febrile neutropenia; grade >=3 neutropenic infection; grade >=3 thrombocytopenia with bleeding; grade 4 thrombocytopenia; (2) non-hematologic: grade >=3 pancreatitis; grade >=3 toxicities (excluding grade >=3 laboratory abnormalities not requiring dose modifications) persisting after optimal treatment with standard medical therapy; symptomatic grade >=3 QTc prolongation, or asymptomatic grade >=3 prolongation that had been confirmed by repeat testing and re-evaluation by a qualified person, and persisted after correction of reversible causes; >=20% decrease from baseline in left ventricular ejection fraction (LVEF); (3) other: failure to deliver at least 16 out of the 21 prescribed daily total doses due to toxicities attributable to study drug; failure to restart dosing after 21 days (1 cycle) delay due to toxicities attributable to study drug.
Query!
Timepoint [1]
0
0
Cycle 1 (21 days)
Query!
Primary outcome [2]
0
0
Percentage of Participants With Overall and Intracranial Objective Response (Phase 2)
Query!
Assessment method [2]
0
0
Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. Results presented here were based on independent central review.
Query!
Timepoint [2]
0
0
3 years
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Overall and Intracranial Objective Response (Phase 1)
Query!
Assessment method [1]
0
0
Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. Results presented here were based on independent central review.
Query!
Timepoint [1]
0
0
3 years
Query!
Secondary outcome [2]
0
0
Time to Tumor Response (TTR) and Intracranial TTR (Phase 1)
Query!
Assessment method [2]
0
0
Time to tumor response (TTR) was defined as the time from the first dose of study treatment to the first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, the onset of PR was taken as the onset of response. TTR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial TTR was only calculated for participants with confirmed intracranial objective response. Results presented here were based on independent central review.
Query!
Timepoint [2]
0
0
3 years
Query!
Secondary outcome [3]
0
0
Duration of Response (DOR) and Intracranial DOR (Phase 1)
Query!
Assessment method [3]
0
0
Duration of Response (DOR) was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurred first. DOR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial DOR was only calculated for participants with confirmed intracranial objective response. Results presented here were based on independent central review.
Query!
Timepoint [3]
0
0
3 years
Query!
Secondary outcome [4]
0
0
Percentage of Participants Achieving Disease Control and Intracranial Disease Control at 12 Weeks (Phase 1)
Query!
Assessment method [4]
0
0
Tumor response was evaluated according to RECIST version 1.1, and disease control was defined as confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD). Intracranial assessment was only performed for participants CNS metastases. Results presented here were based on independent central review.
Query!
Timepoint [4]
0
0
12 weeks
Query!
Secondary outcome [5]
0
0
Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 1)
Query!
Assessment method [5]
0
0
The probability of the first event being a CNS progression, a non-CNS progression, or death was evaluated with a competing risk approach by estimating cumulative incidence functions (range: 0-1) relative to the analysis set. The time to first event being a Competing Event (either "CNS progression" or "non CNS progression" or "Death") was defined as time from first dose until the date of that specific event. Participants not known to have any of the Competing Events were censored on the date they were last assessed for disease status for PFS. Participants who presented one type of event were counted as a competing cause of failure for the analysis of other type of events. For each type of event, the cumulative incidence function corresponding to the nearest time point preceding 1 year is presented. The results are based on independent central review.
Query!
Timepoint [5]
0
0
3 years
Query!
Secondary outcome [6]
0
0
Progression-Free Survival (PFS) (Phase 1)
Query!
Assessment method [6]
0
0
PFS was defined as the time from the first dose of study treatment to the first documentation of objective disease progression or to death on study due to any cause, whichever came first. Results presented here were based on independent central review.
Query!
Timepoint [6]
0
0
3 years
Query!
Secondary outcome [7]
0
0
Overall Survival (OS) (Phase 1)
Query!
Assessment method [7]
0
0
OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.
Query!
Timepoint [7]
0
0
3 years
Query!
Secondary outcome [8]
0
0
Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Single Oral Doses (Phase 1)
Query!
Assessment method [8]
0
0
Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data.
Query!
Timepoint [8]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Query!
Secondary outcome [9]
0
0
Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)
Query!
Assessment method [9]
0
0
Maximum Observed Plasma Concentration (Cmax) of PF-06463922 was observed directly from data.
Query!
Timepoint [9]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups).
Query!
Secondary outcome [10]
0
0
Time for Cmax (Tmax) of PF-06463922 Following Single Oral Doses (Phase 1)
Query!
Assessment method [10]
0
0
Tmax of PF-06463922 was observed directly from data as time of first occurrence.
Query!
Timepoint [10]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Query!
Secondary outcome [11]
0
0
Time for Cmax (Tmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)
Query!
Assessment method [11]
0
0
Tmax of PF-06463922 was observed directly from data as time of first occurrence.
Query!
Timepoint [11]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups).
Query!
Secondary outcome [12]
0
0
Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Single Oral Doses (Phase 1)
Query!
Assessment method [12]
0
0
Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method.
Query!
Timepoint [12]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, and 24 hours post-dose on Day -7 for all other groups.
Query!
Secondary outcome [13]
0
0
Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Multiple Oral Doses (Phase 1)
Query!
Assessment method [13]
0
0
Tau refers to the dosing interval, and it equals to 12 or 24 hours for BID or QD dosing, respectively. AUCtau was determined using linear/log trapezoidal method.
Query!
Timepoint [13]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)
Query!
Secondary outcome [14]
0
0
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 Following Single Oral Doses (Phase 1)
Query!
Assessment method [14]
0
0
AUCinf was calculated as AUClast + (Clast*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase.
Query!
Timepoint [14]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Query!
Secondary outcome [15]
0
0
Apparent Oral Clearance (CL/F) of PF-06463922 Following Single Oral Doses (Phase 1)
Query!
Assessment method [15]
0
0
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Query!
Timepoint [15]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Query!
Secondary outcome [16]
0
0
Apparent Oral Clearance (CL/F) of PF-06463922 Following Multiple Oral Doses (Phase 1)
Query!
Assessment method [16]
0
0
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Query!
Timepoint [16]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)
Query!
Secondary outcome [17]
0
0
Apparent Volume of Distribution (Vz/F) of PF-06463922 Following Single Oral Doses (Phase 1)
Query!
Assessment method [17]
0
0
Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase.
Query!
Timepoint [17]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Query!
Secondary outcome [18]
0
0
Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 1)
Query!
Assessment method [18]
0
0
Rac was calculated as Day 15 AUCtau/Day -7 AUCtau or Day 1 AUCtau, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (12 and 24 hours for BID and QD dosing regimen, respectively).
Query!
Timepoint [18]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)
Query!
Secondary outcome [19]
0
0
Terminal Half-Life of PF-06463922 Following Single Oral Doses (Phase 1)
Query!
Assessment method [19]
0
0
Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase.
Query!
Timepoint [19]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.
Query!
Secondary outcome [20]
0
0
Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 1)
Query!
Assessment method [20]
0
0
Rss was calculated as Day 15 AUCtau/Day -7 AUCinf, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (12 and 24 hours for BID and QD dosing regimen, respectively), and AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Query!
Timepoint [20]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24 hours post-dose on Cycle 1 Day 15 (24-hour samples not collected for BID groups)
Query!
Secondary outcome [21]
0
0
Renal Clearance (CLr) of PF-06463922 (Phase 1)
Query!
Assessment method [21]
0
0
Renal clearance was calculated as Aetau/AUCtau, where Aetau was the cumulative amount of drug recovered unchanged in urine up to dosing interval tau (24 hours for QD dosing regimen), and AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen).
Query!
Timepoint [21]
0
0
0-4 hours, 4-12 hours and 12-24 hours post-dose on Cycle 1 Day 15
Query!
Secondary outcome [22]
0
0
Percent of PF-06463922 Recovered Unchanged in Urine up to Dosing Interval (AEtau%) (Phase 1)
Query!
Assessment method [22]
0
0
Dosing interval was 24 hours for QD dosing regimen. Aetau% was calculated as 100*Ae24/dose, where Ae24 was the cumulative amount of drug recovered unchanged in urine up to 24 hours post-dose.
Query!
Timepoint [22]
0
0
0-4 hours, 4-12 hours and 12-24 hours post-dose on Cycle 1 Day 15
Query!
Secondary outcome [23]
0
0
Maximum Observed Plasma Concentration (Cmax) of Midazolam (Phase 1)
Query!
Assessment method [23]
0
0
Cmax of midazolam was observed directly from data. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflected the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflected the PK assessment after multiple doses of PF-06463922 were administered.
Query!
Timepoint [23]
0
0
Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Query!
Secondary outcome [24]
0
0
Time for Cmax (Tmax) of Midazolam (Phase 1)
Query!
Assessment method [24]
0
0
Tmax of midazolam was observed directly from data as time of first occurrence. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
Query!
Timepoint [24]
0
0
Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Query!
Secondary outcome [25]
0
0
Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam (Phase 1)
Query!
Assessment method [25]
0
0
Area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast) of midazolam was determined using linear/log trapezoidal method. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
Query!
Timepoint [25]
0
0
Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Query!
Secondary outcome [26]
0
0
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Midazolam (Phase 1)
Query!
Assessment method [26]
0
0
AUCinf was calculated as AUClast + (Clast*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
Query!
Timepoint [26]
0
0
Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Query!
Secondary outcome [27]
0
0
Apparent Oral Clearance (CL/F) of Midazolam (Phase 1)
Query!
Assessment method [27]
0
0
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
Query!
Timepoint [27]
0
0
Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Query!
Secondary outcome [28]
0
0
Apparent Volume of Distribution (Vz/F) of Midazolam (Phase 1)
Query!
Assessment method [28]
0
0
Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
Query!
Timepoint [28]
0
0
Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Query!
Secondary outcome [29]
0
0
Terminal Half-Life of Midazolam (Phase 1)
Query!
Assessment method [29]
0
0
Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.
Query!
Timepoint [29]
0
0
Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Query!
Secondary outcome [30]
0
0
Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 1)
Query!
Assessment method [30]
0
0
Plasma circulating nucleic acid (CNA) samples were analyzed for ALK kinase domain mutations by digital polymerase chain reaction (PCR) BEAMing technology. Number of participants with one or more ALK mutations is presented.
Query!
Timepoint [30]
0
0
Screening
Query!
Secondary outcome [31]
0
0
Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 1)
Query!
Assessment method [31]
0
0
Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented.
Query!
Timepoint [31]
0
0
Screening
Query!
Secondary outcome [32]
0
0
Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 1)
Query!
Assessment method [32]
0
0
European Organisation for Research and Treatment of Cancer Core Quality of Life Questionaires (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhoea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.
Query!
Timepoint [32]
0
0
Baseline, Day 1 of Cycles 2-25, Day 1 of every other cycle after Cycle 25, end of treatment (up to 3 years)
Query!
Secondary outcome [33]
0
0
Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 1)
Query!
Assessment method [33]
0
0
EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. The scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.
Query!
Timepoint [33]
0
0
Baseline, Day 1 of Cycles 2-25, Day 1 of every other cycle after Cycle 25, end of treatment (up to 3 years)
Query!
Secondary outcome [34]
0
0
Change From Baseline in Mini Mental State Examination (MMSE) Score (Phase 1)
Query!
Assessment method [34]
0
0
In Phase 1, the MMSE was collected to assess mental status. The MMSE is a 30 item questionnaire that tests 5 areas of cognitive function: orientation, registration, attention and calculation, recall and language. The maximum score is 30. A score of 23 or lower is indicative of cognitive impairment. The MMSE was removed under Amendment 6 of the study protocol, and not required for Phase 2, as the tool was not considered meaningful for assessment of cognitive function.
Query!
Timepoint [34]
0
0
Baseline, Day 1 of each cycle, and end of treatment (up to 3 years)
Query!
Secondary outcome [35]
0
0
Time to Tumor Response (TTR) and Intracranial TTR (Phase 2)
Query!
Assessment method [35]
0
0
Time to tumor response (TTR) was defined as the time from the first dose of study treatment to the first documentation of objective tumor response (CR or PR). For participants whose objective response proceeded from PR to CR, the onset of PR was taken as the onset of response. TTR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial TTR was only calculated for participants with confirmed intracranial objective response. Results presented here were based on independent central review.
Query!
Timepoint [35]
0
0
3 years
Query!
Secondary outcome [36]
0
0
Duration of Response (DOR) and Intracranial DOR (Phase 2)
Query!
Assessment method [36]
0
0
Duration of Response (DOR) was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurred first. DOR was only calculated for the subgroup of participants with a confirmed objective tumor response. Intracranial DOR was only calculated for participants with confirmed intracranial objective response. Results presented here were based on independent central review.
Query!
Timepoint [36]
0
0
3 years
Query!
Secondary outcome [37]
0
0
Percentage of Participants Achieving Disease Control and Intracranial Disease Control at 12 Weeks (Phase 2)
Query!
Assessment method [37]
0
0
Tumor response was evaluated according to RECIST version 1.1, and disease control was defined as confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD). Intracranial assessment was only performed for participants CNS metastases. Results presented here were based on independent central review.
Query!
Timepoint [37]
0
0
12 weeks
Query!
Secondary outcome [38]
0
0
Time to Progression (TTP) on the Last Prior Therapy (Phase 2)
Query!
Assessment method [38]
0
0
TTP on the last prior therapy was defined as time from the first dose date of the last prior treatment regimen to the date of progression.
Query!
Timepoint [38]
0
0
3 years
Query!
Secondary outcome [39]
0
0
Time to Tumor Progression (TTP) and Intracranial TTP (Phase 2)
Query!
Assessment method [39]
0
0
Time to progression (TTP) was defined as the time from the first dose of study treatment to the first documentation of objective disease progression. Intracranial TTP was defined as the time from the first dose of study treatment to the date of the first documentation of objective progression of intracranial disease, based on either new brain metastases or progression of existing brain metastases. Results presented here were based on independent central review.
Query!
Timepoint [39]
0
0
3 years
Query!
Secondary outcome [40]
0
0
Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 2)
Query!
Assessment method [40]
0
0
The probability of the first event being a CNS progression, a non-CNS progression, or death was evaluated with a competing risk approach by estimating cumulative incidence functions (range: 0-1) relative to the analysis set. The time to first event being a Competing Event (either "CNS progression" or "non CNS progression" or "Death") was defined as time from first dose until the date of that specific event. Participants not known to have any of the Competing Events were censored on the date they were last assessed for disease status for PFS. Participants who presented one type of event were counted as a competing cause of failure for the analysis of other type of events. For each type of event, the cumulative incidence function corresponding to the nearest time point preceding 1 year is presented. The results are based on independent central review.
Query!
Timepoint [40]
0
0
3 years
Query!
Secondary outcome [41]
0
0
Progression-Free Survival (PFS) (Phase 2)
Query!
Assessment method [41]
0
0
PFS was defined as the time from the first dose of study treatment to the first documentation of objective disease progression or to death on study due to any cause, whichever came first. Results presented here were based on independent central review.
Query!
Timepoint [41]
0
0
3 years
Query!
Secondary outcome [42]
0
0
Overall Survival (Phase 2)
Query!
Assessment method [42]
0
0
OS was defined as the time from first dose to the date of death due to any cause. For participants still alive at the time of analysis, the OS time was censored on the last date the participants were known to be alive. Estimates of OS and its 95% confidence interval were determined using Kaplan-Meier method.
Query!
Timepoint [42]
0
0
3 years
Query!
Secondary outcome [43]
0
0
Maximum Observed Plasma Concentration (Cmax) of PF-06463922 (Phase 2)
Query!
Assessment method [43]
0
0
Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data.
Query!
Timepoint [43]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Query!
Secondary outcome [44]
0
0
Time for Cmax (Tmax) of PF-06463922 (Phase 2)
Query!
Assessment method [44]
0
0
Tmax of PF-06463922 was observed directly from data as time of first occurrence.
Query!
Timepoint [44]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Query!
Secondary outcome [45]
0
0
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 (Phase 2)
Query!
Assessment method [45]
0
0
AUCinf was calculated as AUClast + (Clast*/kel), where AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel was the rate constant for terminal phase.
Query!
Timepoint [45]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7
Query!
Secondary outcome [46]
0
0
Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 (Phase 2)
Query!
Assessment method [46]
0
0
Tau refers to the dosing interval, and it equals to 24 hours for QD dosing which was adopted in Phase 2. AUCtau was determined using linear/log trapezoidal method.
Query!
Timepoint [46]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Query!
Secondary outcome [47]
0
0
Apparent Oral Clearance (CL/F) of PF-06463922 (Phase 2)
Query!
Assessment method [47]
0
0
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose/AUCinf, where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Query!
Timepoint [47]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Query!
Secondary outcome [48]
0
0
Apparent Volume of Distribution (Vz/F) of PF-06463922 (Phase 2)
Query!
Assessment method [48]
0
0
Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug, and calculated as dose/(AUCinf*kel), where AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time, kel was the rate constant for terminal phase.
Query!
Timepoint [48]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7
Query!
Secondary outcome [49]
0
0
Terminal Half-Life of PF-06463922 (Phase 2)
Query!
Assessment method [49]
0
0
Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase.
Query!
Timepoint [49]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7
Query!
Secondary outcome [50]
0
0
Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 2)
Query!
Assessment method [50]
0
0
Rac was calculated as Day 15 AUCtau/Day -7 AUCtau, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen which was adopted in Phase 2).
Query!
Timepoint [50]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Query!
Secondary outcome [51]
0
0
Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 2)
Query!
Assessment method [51]
0
0
Rss was calculated as Day 15 AUCtau/Day -7 AUCinf, where AUCtau was the area under the plasma concentration-time profile from time 0 to time tau (24 hours for QD dosing regimen which was adopted in Phase 2), and AUCinf was the area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Query!
Timepoint [51]
0
0
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15
Query!
Secondary outcome [52]
0
0
Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 2)
Query!
Assessment method [52]
0
0
Plasma CNA samples were analyzed for ALK kinase domain mutations by Next Generation Sequencing (NGS). Number of participants with one or more ALK mutations is presented.
Query!
Timepoint [52]
0
0
Screening
Query!
Secondary outcome [53]
0
0
Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 2)
Query!
Assessment method [53]
0
0
Tumor tissues from archived tissue specimens and/or a de novo biopsy were analyzed for ALK kinase domain mutations. Number of participants with one or more ALK mutations is presented.
Query!
Timepoint [53]
0
0
Screening
Query!
Secondary outcome [54]
0
0
Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 2)
Query!
Assessment method [54]
0
0
European Organisation for Research and Treatment of Cancer Core Quality of Life Questionaires (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhoea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.
Query!
Timepoint [54]
0
0
3 years
Query!
Secondary outcome [55]
0
0
Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 2)
Query!
Assessment method [55]
0
0
EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. The scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.
Query!
Timepoint [55]
0
0
3 years
Query!
Secondary outcome [56]
0
0
Number of Participants With Treatment-Emergent Adverse Events (Phase 1 and Phase 2)
Query!
Assessment method [56]
0
0
AE was defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of the causal relationship to study treatment. Treatment-emergent AEs (TEAEs) were defined as AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Causality to study treatment was determined by the investigator. Severity was graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Query!
Timepoint [56]
0
0
3 years
Query!
Secondary outcome [57]
0
0
Number of Participants With Laboratory Abnormalities (Phase 1 and Phase 2) - Hematology
Query!
Assessment method [57]
0
0
Hematology evaluation included hemoglobin, platelets, white blood cell, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils and absolute basophils.
Query!
Timepoint [57]
0
0
3 years
Query!
Secondary outcome [58]
0
0
Number of Participants With Laboratory Abnormalities (Phase 1 and Phase 2) - Chemistry
Query!
Assessment method [58]
0
0
Chemistry evaluation included alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, blood urea nitrogen (BUN) or urea, creatinine, uric acid, glucose (non-fasted), albumin, phosphorus or phosphate, serum total amylase and serum lipase.
Query!
Timepoint [58]
0
0
3 years
Query!
Secondary outcome [59]
0
0
Number of Participants With Laboratory Abnormalities (Phase 1 and Phase 2) - Coagulation, Lipids and Urinalysis
Query!
Assessment method [59]
0
0
Coagulation evaluation included activated partial thromboplastin time, international normalized ratio (INR), and prothrombin time. Lipid evaluation included total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides. Urinalysis included urine protein and urine blood.
Query!
Timepoint [59]
0
0
3 years
Query!
Secondary outcome [60]
0
0
Number of Participants With Vital Signs Data Meeting Pre-defined Criteria (Phase 1 and Phase 2)
Query!
Assessment method [60]
0
0
Blood pressure (BP), including systolic BP (SBP) and diastolic BP (DBP), and pulse rate were recorded in sitting position. Body weight was also measured.
Query!
Timepoint [60]
0
0
Baseline, Days 1, 8 and 15 of Cycle 1, Day 1 of Cycles 2-25 for Phase 1 (Cycles 2-38 for Phase 2), Day 1 of every other cycle thereafter, end of treatment (up to 3 years)
Query!
Secondary outcome [61]
0
0
Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Percent in Left Ventricular Ejection Fraction (LVEF) (Phase 1 and Phase 2)
Query!
Assessment method [61]
0
0
Left Ventricular Ejection Fraction (LVEF) was determined by electrocardiogram (ECG) measurement. Baseline was defined as the measurement prior to the first dose of study treatment.
Query!
Timepoint [61]
0
0
Baseline, Day 1 of Cycles 2-3, Day 1 of every other cycle from Cycle 5 up to 18 months for Phase 1 (up to 30 months for Phase 2), every 4 cycles thereafter, and end of treatment (up to 3 years)
Query!
Secondary outcome [62]
0
0
Number of Participants With Absolute Values and Change From Baseline in QTcF Meeting Pre-defined Criteria (Phase 1 and Phase 2)
Query!
Assessment method [62]
0
0
Triplicate 12-lead electrocardiograms (ECGs) were performed approximately 2 minutes apart to determine mean QTc interval (QT interval corrected for heart rate). QT interval was corrected for heart rate using Fridericia's formula to provide QTcF. Absolute values and changes from baseline were summarized according to pre-defined criteria. Baseline was defined as the last evaluation on or prior to the first dose of study treatment.
Query!
Timepoint [62]
0
0
Phase 1: baseline, Days 1, 8 and 15 of Cycle 1, Day 1 of Cycles 2-25, end of treatment (up to 3 years); Phase 2: baseline, Days 1, 8 and 15 of Cycle 1, Day 1 of Cycles 2-5, end of treatment (up to 3 years)
Query!
Secondary outcome [63]
0
0
Number of Participants With Suicidal Ideation and Suicidal Behavior (Phase 2)
Query!
Assessment method [63]
0
0
The Columbia Suicide Severity Rating Scale (C-SSRS) was used to analyze participants' suicidal ideation and behavior, and it is a unique, simple and short method of assessing both behavior and ideation that tracks all suicidal events and provides a summary of suicidality. It assesses the lethality of attempts and other features of ideation (frequency, duration, controllability, reasons for ideation and deterrents), all of which are significantly predictive of completed suicide.
Query!
Timepoint [63]
0
0
3 years
Query!
Secondary outcome [64]
0
0
Change From Baseline in Total Scores for Beck Depression Inventory (BDI)-II (Mood Assessment) (Phase 2)
Query!
Assessment method [64]
0
0
The Beck Depression Inventory (BDI)-II is a 21-item self-report scale, with each item rated by participants on a 4-point scale (ranging from 0-3). The scale includes items capturing mood, (loss of pleasure, sadness, and irritability), suicidal ideation, and cognitive signs (punitive thoughts, self-criticism, self-dislike, pessimism, and poor concentration) as well as somatic signs (appetite, sleep, fatigue and libido). Scores were obtained by adding up the total points from the series of answers. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are as follows: 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; 29-63: severe depression.
Query!
Timepoint [64]
0
0
Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Query!
Secondary outcome [65]
0
0
Change From Baseline in Total Scores for Detection Test (Cognitive Function Assessment) (Phase 2)
Query!
Assessment method [65]
0
0
The Detection Test is a measure of psychomotor function and uses a well validated simple reaction time paradigm with playing card stimuli. In this test, the on-screen instructions ask: "Has the card turned over?". A playing card is presented face down in the center of the screen. The card flips over so it is face up. As soon as the card flips over the participant must press "Yes". The participant is encouraged to work as quickly as they can and be as accurate as possible. The speed and accuracy of each response are recorded and mean of the log10 transformed reaction times for correct responses is calculated. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.
Query!
Timepoint [65]
0
0
Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Query!
Secondary outcome [66]
0
0
Change From Baseline in Total Scores for Identification Test (Cognitive Function Assessment) (Phase 2)
Query!
Assessment method [66]
0
0
The Identification Test is a measure of visual attention and uses a well validated choice reaction time paradigm with playing card stimuli. In this task, the playing cards are all red or black jokers. The on-screen instructions ask: "Is the card red?". A playing card is presented face down in the center of the screen. The card flips over so it is face up. As soon as it flips over the participant must decide whether the card is red or not. If it is red the participant should press "Yes", and if it is not red the participant should press "No". The participant is encouraged to work as quickly and accurately as possible. The speed and accuracy of each response are recorded and mean of the log10 transformed reaction times for correct responses is calculated. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.
Query!
Timepoint [66]
0
0
Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Query!
Secondary outcome [67]
0
0
Change From Baseline in Total Scores for One Back Test (Cognitive Function Assessment) (Phase 2)
Query!
Assessment method [67]
0
0
The One Back Test is a measure of working memory and uses a well validated n back paradigm with playing cards. In this task, the on-screen instructions ask: "Is the previous card the same?". A playing card is presented in the center of the screen. The participant must decide whether the card is the same as the previous card. If it is the same the participant should press "Yes", and if not press "No". The participant is encouraged to work as quickly and accurately as possible. The speed and accuracy of each response are recorded, mean of the log10 transformed reaction times for correct responses is used to demonstrate speed of performance, and the arcsine transformation of the square root of the proportion of correct responses is used to demonstrate accuracy. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.
Query!
Timepoint [67]
0
0
Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Query!
Secondary outcome [68]
0
0
Change From Baseline in Total Scores for International Shopping List Test (Cognitive Function Assessment) (Phase 2)
Query!
Assessment method [68]
0
0
The International Shopping List task is a measure of verbal learning and uses a well validated list learning paradigm administered using a computer. High frequencies, high imagery, concrete nouns (items from a shopping list) were read to the participant at the rate of one word every 2 seconds. Once all 12 words had been read, the participant was asked to recall as many of the words as quickly as possible. The words recalled by the participant were marked on the computer screen. When the participant could recall no more words, the same list was read again. The words recalled by the participant were recorded. This was then repeated a third time. Total number of correct responses on 3 consecutive trials at a single assessment was recorded. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.
Query!
Timepoint [68]
0
0
Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Query!
Secondary outcome [69]
0
0
Change From Baseline in Total Scores for International Shopping List Test-Delayed Recall (Cognitive Function Assessment) (Phase 2)
Query!
Assessment method [69]
0
0
This test was performed in the same way as the International Shopping List Test, with the exception that, the delayed recall condition required the participant to recall the words from the list 15 30 minutes later without having the list read again. During the recognition condition, the qualified personnel read a shopping list item that may or may not have been on the original list and the participant had to respond either affirmatively (if the item was on the original list) or negatively (if it was not). Total number of correct responses made in remembering the word list after a delay was recorded. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.
Query!
Timepoint [69]
0
0
Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria
- Evidence of histologically or cytologically confirmed diagnosis of metastatic NSCLC
(Stage IV, AJCC v7.0) that carries an ALK rearrangement, as determined by the Food and
Drug Administration (FDA) approved FISH assay (Abbott Molecular Inc) or by
Immunohistochemistry (IHC) (Ventana Inc), or a ROS1 rearrangement as determined by
FISH or RT PCR or Next Generation Sequencing (NGS) via a local diagnostic test (LDT).
All patients (ALK positive and ROS1 positive) must have archival tissue sample
available and collected prior to enrollment.
- Disease Status Requirements:
Phase 1: ALK-positive NSCLC and ROS1-positive patients must either be treatment naïve in
the advanced setting or have had disease progression after at least 1 previous ALK/ROS1
inhibitor therapy(ies).
Phase 2:
ALK-positive NSCLC patients must either be or have had:
- Treatment naïve (ie, no prior chemotherapy in the metastatic disease setting and no
prior ALK inhibitor therapy allowed).
- Disease progression after crizotinib only. No prior chemotherapy is allowed in the
metastatic disease setting.
- Disease progression after crizotinib and 1 or 2 prior regimens of chemotherapy in the
metastatic disease setting.
- Disease progression after 1 prior ALK inhibitor therapy other than crizotinib.
Patients may have had any number of prior chemotherapy regimens in any disease
setting.
- Disease progression after 2 prior ALK inhibitor therapies. Patients may have had any
number of prior chemotherapy regimens in any disease setting.
- Disease progression after 3 prior ALK inhibitor therapies. Patients may have had any
number of prior chemotherapy regimens in any disease setting.
ROS1-positive NSCLC patients may be:
- Treatment naïve (ie, no prior chemotherapy in the metastatic disease setting and no
prior ROS inhibitor therapy).
- Any number of prior therapies (ie, chemotherapy and/or ROS inhibitor therapies).
- Tumor Requirements:
All Patients must have at least one measurable target extracranial lesion according to
RECIST v1.1. In addition patients with asymptomatic CNS metastases (including patients
asymptomatic by means of stable or decreasing doses of steroids within the last 2 weeks
prior to study entry) will be eligible. Patients who have leptomeningeal disease (LM) or
carcinomatous meningitis (CM) are eligible.
- Adequate Bone Marrow, Pancreatic Function, Renal Function and Liver Function.
- Negative Serum pregnancy test for females of childbearing potential
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
- Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study
entry. Whole brain radiation must have completed at least 4 weeks prior to study
entry.
- Systemic anti cancer therapy completed within a minimum of 5 half lives of study
entry.
- Prior therapy with an antibody or drug specifically targeting T-cell co-stimulation or
immune checkpoint pathways, including, but not limited to, anti-PD-1, anti-PD-L1,
anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte associated antigen 4
(anti-CTLA-4) antibody.
- Active and clinically significant bacterial, fungal, or viral infection including
hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or
acquired immunodeficiency syndrome (AIDS) related illness.
- Clinically significant cardiovascular disease (that is, active or <3 months prior to
enrollment): cerebral vascular accident/stroke, myocardial infarction, unstable
angina, congestive heart failure (New York Heart Association Classification Class =
II), second-degree or third-degree AV block (unless paced) or any AV block with PR
>220 msec. Ongoing cardiac dysrhythmias of NCI CTCAE Grade =2, uncontrolled atrial
fibrillation of any grade, bradycardia defined as <50 bpm (unless patient is otherwise
healthy such as long-distance runners, etc.), machine-read ECG with QTc >470 msec, or
congenital long QT syndrome.
- History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial
fibrosis or interstitial lung disease including a history of pneumonitis,
hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease,
obliterative bronchiolitis and pulmonary fibrosis.
- Current use or anticipated need for food or drugs that are known strong or moderate
CYP3A4 inhibitors, inducers and substrates; drugs that are CYP2C9 substrates; drugs
that are sensitive CYP2B6 substrates; drugs that are strong CYP2C19 inhibitors; drugs
that are strong CYP2C8 inhibitors; and drugs that are P-gp substrates.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/01/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
24/05/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
334
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Chris O'Brien Lifehouse - Sydney Local Health District [rpa]
Query!
Recruitment hospital [2]
0
0
Chris O'Brien Lifehouse - Sydney
Query!
Recruitment hospital [3]
0
0
Royal Prince Alfred Hospital - Sydney
Query!
Recruitment hospital [4]
0
0
Peter MacCallum Cancer Centre - Melbourne
Query!
Recruitment hospital [5]
0
0
Royal Melbourne Hospital - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2050 - Sydney Local Health District [rpa]
Query!
Recruitment postcode(s) [2]
0
0
2050 - Sydney
Query!
Recruitment postcode(s) [3]
0
0
3000 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
District of Columbia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Massachusetts
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Michigan
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Missouri
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Ohio
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Pennsylvania
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Tennessee
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Edegem
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
British Columbia
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Ontario
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Grenoble Cedex 9
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Rennes Cedex 9
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Toulouse Cedex 9
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Villejuif Cedex
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Villejuif
Query!
Country [21]
0
0
Germany
Query!
State/province [21]
0
0
Cologne
Query!
Country [22]
0
0
Hong Kong
Query!
State/province [22]
0
0
Shatin
Query!
Country [23]
0
0
Italy
Query!
State/province [23]
0
0
Aviano (PN)
Query!
Country [24]
0
0
Italy
Query!
State/province [24]
0
0
Milano
Query!
Country [25]
0
0
Italy
Query!
State/province [25]
0
0
Perugia
Query!
Country [26]
0
0
Japan
Query!
State/province [26]
0
0
Aichi
Query!
Country [27]
0
0
Japan
Query!
State/province [27]
0
0
Chiba
Query!
Country [28]
0
0
Japan
Query!
State/province [28]
0
0
Ehime
Query!
Country [29]
0
0
Japan
Query!
State/province [29]
0
0
Hokkaido
Query!
Country [30]
0
0
Japan
Query!
State/province [30]
0
0
Hyogo
Query!
Country [31]
0
0
Japan
Query!
State/province [31]
0
0
Osaka
Query!
Country [32]
0
0
Japan
Query!
State/province [32]
0
0
Shizuoka
Query!
Country [33]
0
0
Japan
Query!
State/province [33]
0
0
Tokyo
Query!
Country [34]
0
0
Japan
Query!
State/province [34]
0
0
Fukuoka
Query!
Country [35]
0
0
Japan
Query!
State/province [35]
0
0
Koto-ku, Tokyo
Query!
Country [36]
0
0
Korea, Republic of
Query!
State/province [36]
0
0
Seoul
Query!
Country [37]
0
0
Singapore
Query!
State/province [37]
0
0
Singapore
Query!
Country [38]
0
0
Spain
Query!
State/province [38]
0
0
Madrid
Query!
Country [39]
0
0
Spain
Query!
State/province [39]
0
0
Navarra
Query!
Country [40]
0
0
Spain
Query!
State/province [40]
0
0
Barcelona
Query!
Country [41]
0
0
Switzerland
Query!
State/province [41]
0
0
Lausanne
Query!
Country [42]
0
0
Switzerland
Query!
State/province [42]
0
0
Winterthur
Query!
Country [43]
0
0
Taiwan
Query!
State/province [43]
0
0
Taipei
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported
outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients
and ROS1+ advanced non small cell lung cancer patients .
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01970865
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01970865
Download to PDF